Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.
from The Medical News http://ift.tt/1IxZDln
from The Medical News http://ift.tt/1IxZDln
No comments:
Post a Comment